Product Description
Mechanisms of Action: IL22 Antagonist
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Subcutaneous,Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Arthritis, Rheumatoid|Dermatitis, Atopic
Phase 1: Healthy Volunteers|Psoriasis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
JKR-0766 | P2 |
Completed |
Dermatitis, Atopic |
2016-02-01 |
|
3199K1-2001 | P2 |
Completed |
Arthritis, Rheumatoid |
2011-02-18 |
|
2008-006936-37 | P2 |
Completed |
Arthritis, Rheumatoid |
2011-02-18 |
|
JapicCTI-101247 | P2 |
Completed |
Arthritis, Rheumatoid |
2011-02-18 |